Sarepta Therapeutics Surges to 451st in Trading Volume with $192 Million in Shares Traded

On May 20, 2025, Sarepta Therapeutics (SRPT) saw a significant increase in trading volume, with a total of $192 million in shares traded, marking a 40.6% rise from the previous day. This surge placed Sarepta at the 451st position in terms of trading volume for the day. The stock price also rose by 5.40%, marking the third consecutive day of gains, with a total increase of 13.38% over the past three days.

During the Q1 earnings call, Sarepta reported revenue of $744.9 million, surpassing analyst estimates of $693.5 million. This represents an 80.2% year-on-year growth and a 7.4% beat. However, the adjusted earnings per share (EPS) were reported at -$3.42, missing analyst estimates of -$0.65.

Following the earnings call, JPMorgan adjusted its price target for Sarepta, reducing it from $169 to $84. This decision was based on updated company projections and the recent safety event and administrative delays reported by Sarepta.

Sarepta also presented new data on protein expression and other key metrics during the Q1 earnings call, providing insights into the company's ongoing research and development efforts. The company's presentation at the American Society of Gene & Cell Therapy (ASGCT) annual meeting further highlighted its advancements in gene therapy.